Good Is Never Good Enough For Patients: BLUE Toolbox Strategy
At bluebird, good is never good enough. Driven by our passion to lead the gene therapy revolution, we are constantly asking “What could go wrong?” and ”What could we do better?.” Our anti pure play model is essential to our ability to outsmart disease – we simply cannot have a singular focus if we want to achieve our goal of developing and bringing to market the most advanced products. For us, it has always been about the possibility to cure severe genetic diseases. And as we fully engage our toolbox, we are working to make hope for a healthy life a reality. vFuture
v1.0
LentiGlobin
v2.0
LentiGlobin
& Enhancers
Product Engine
LentiGlobin
Novel areas;; autoimmune In vivo gene editing
Tr a n s d u c t i o n
Lentivirus
BCMA (bb2121)
Durability
NASDAQ: BLUE
BCMA
& PI3Ki (bb21217
)
Optimized
severe genetic
disease
products
BCMA
& Solid Tumors
New & enhanced oncology
products